SG11201504779YA - Methods and compositions relating to treatment of cancer - Google Patents

Methods and compositions relating to treatment of cancer

Info

Publication number
SG11201504779YA
SG11201504779YA SG11201504779YA SG11201504779YA SG11201504779YA SG 11201504779Y A SG11201504779Y A SG 11201504779YA SG 11201504779Y A SG11201504779Y A SG 11201504779YA SG 11201504779Y A SG11201504779Y A SG 11201504779YA SG 11201504779Y A SG11201504779Y A SG 11201504779YA
Authority
SG
Singapore
Prior art keywords
cancer
treatment
methods
compositions relating
relating
Prior art date
Application number
SG11201504779YA
Inventor
Joshua E Allen
Wafik S El-Deiry
Arun K Sharma
Shantu G Amin
Rosalyn Irby
Original Assignee
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Res Found filed Critical Penn State Res Found
Publication of SG11201504779YA publication Critical patent/SG11201504779YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201504779YA 2012-12-20 2013-12-20 Methods and compositions relating to treatment of cancer SG11201504779YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740126P 2012-12-20 2012-12-20
PCT/US2013/076869 WO2014100565A1 (en) 2012-12-20 2013-12-20 Methods and compositions relating to treatment of cancer

Publications (1)

Publication Number Publication Date
SG11201504779YA true SG11201504779YA (en) 2015-07-30

Family

ID=49950064

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504779YA SG11201504779YA (en) 2012-12-20 2013-12-20 Methods and compositions relating to treatment of cancer

Country Status (10)

Country Link
US (1) US20150328310A1 (en)
EP (1) EP2934583A1 (en)
JP (1) JP2016503063A (en)
KR (1) KR20150099588A (en)
CN (1) CN105007940B (en)
AU (1) AU2013361164A1 (en)
CA (1) CA2894547A1 (en)
RU (1) RU2015129366A (en)
SG (1) SG11201504779YA (en)
WO (1) WO2014100565A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811255WA (en) * 2016-06-29 2019-01-30 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US5648097A (en) 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
WO2008128189A1 (en) * 2007-04-13 2008-10-23 The Penn State Research Foundation Anti-cancer compositions and methods

Also Published As

Publication number Publication date
US20150328310A1 (en) 2015-11-19
CN105007940B (en) 2017-08-25
KR20150099588A (en) 2015-08-31
CA2894547A1 (en) 2014-06-26
EP2934583A1 (en) 2015-10-28
JP2016503063A (en) 2016-02-01
CN105007940A (en) 2015-10-28
AU2013361164A1 (en) 2015-07-02
WO2014100565A1 (en) 2014-06-26
RU2015129366A (en) 2017-01-25

Similar Documents

Publication Publication Date Title
EP2831001A4 (en) Water treatment compositions and methods of use
HK1211832A1 (en) Novel compositions and uses of anti-hypertension agents for cancer therapy
HK1200739A1 (en) Diagnostic methods and compositions for treatment of cancer
IL238177A0 (en) Methods and compositions for the treatment of cancer
EP2688594A4 (en) Methods and compositions for the treatment of cancer
HK1200086A1 (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer p62
HK1212251A1 (en) Topical compositions and methods of use
HK1210187A1 (en) Compositions and methods related to prevention and treatment of rabies infection
HK1214128A1 (en) Treatment of cancer
EP2812451A4 (en) Methods and compositions relating to fusions of ros1 for diagnosing and treating cancer
SG11201504300VA (en) Accelerated prediction of cancer progression and response to treatment
IL234606B (en) Novel methods and composition for treatment of disease
HK1205254A1 (en) Methods of treatment of cancer
PL2892556T3 (en) Compositions and methods relating to the treatment of diseases
GB201217892D0 (en) Treatment of cancer
EP2755668A4 (en) Hyr1-derived compositions and methods of treatment using same
HK1204956A1 (en) Treatment of cancer
EP2958591A4 (en) Methods and compositions relating to the treatment of cancer
SI2892925T1 (en) Combination treatment of cancer
ZA201408057B (en) Compositions and methods for the treatment of moderate to severe pain
EP2928456A4 (en) Methods and compositions for treatment of cancer
ZA201506392B (en) Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
PL3079684T3 (en) Compositions and methods for the treatment of diseases related to the renin-angiotensin-system
SG11201504779YA (en) Methods and compositions relating to treatment of cancer
EP2825184A4 (en) Compositions and methods for treatment of pain